Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | Blank 3 | Frequency | |
|---|---|---|---|---|---|---|---|
| 1 | 3 | impairment of gastrointestinal function | 33 | gi disease that may significantly alter the absorption of the study drugs e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 13 | or small bowel resection | 50 |
| 2 | 57 | impairment of gastrointestinal gi function | 27 | gi disease that may significantly alter the absorption of study drug e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 10 | 10 | |
| 3 | 56 | patient has impairment of gastrointestinal gi function | 15 | gastrointestinal disease that may significantly alter the absorption of everolimus e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 8 | small bowel resection | 9 |
| 4 | 68 | impaired gastrointestinal gi function | 11 | gi disease that may significantly alter the absorption of bkm120 e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 7 | small bowel resection or gastric bypass surgery | 8 |
| 5 | 13 | inability to swallow | 3 | gastrointestinal disease e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 5 | or small bowel resection patients with unresolved diarrhea will be excluded as previously indicated | 8 |
| 6 | 22 | patients must be able to take oral medications patient may not have any impairment of gastrointestinal function | 3 | 4 | or significant small bowel resection | 4 | |
| 7 | 60 | patient is not able to swallow oral medication and / | 3 | gi disease that may significantly alter the absorption of oral byl719 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 4 | or small bowel resection . | 4 |
| 8 | 69 | patient has impairment of gi function | 3 | gastrointestinal disease that may significantly alter the absorption of drugs e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 3 | or small bowel resection that womcLd preclude use of oral medications | 3 |
| 9 | 1 | patients must be able to take oral medications patients may not have any impairment of gastrointestinal function | 2 | has impairment of gastrointestinal gi function or gi disease that may significantly alter the absorption of the study drugs e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 3 | . | 3 |
| 10 | 4 | inability to take oral medication | 2 | gi disease that may significantly alter the absorption of ceritinib e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea or | 3 | or small bowel resection a nasogastric tube ng tube or gastric tube g tube is allowed | 2 |
| 11 | 26 | patients with impairment of gastrointestinal function | 2 | gastrointestinal disease that may significantly alter the absorption of palbociclib e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 2 | small bowel resection uncontrolled nausea or vomiting or grade > = 3 diarrhea of any etiology based on treating physician assessment | 2 |
| 12 | 28 | impaired gastrointestinal function | 2 | gastrointestinal disease that may significantly alter the absorption of rad001 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 2 | or extensive small bowel resection | 2 |
| 13 | 54 | 2 | impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the drugs e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 2 | or extensive small bowel resection participants with unresolved diarrhea > = ctcae grade 2 will be excluded as previously indicated | 2 | |
| 14 | 58 | patient is unable to swallow oral medications | 2 | poorly controlled gastrointestinal disease that may significantly alter the absorption of oral byl719 e . g . crohn s disease mcLcerative colitis | 2 | or small bowel resection are not eligible for participation | 2 |
| 15 | 59 | known impairment of gastrointestinal gi function | 2 | gastrointestinal disease that may significantly alter the absorption of study drugs e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 2 | or any other uncontrolled gastrointestinal condition eg nausea diarrhea or vomiting that might impair the bioavailability of e7046 | 1 |
| 16 | 62 | participants with impairment of gastrointestinal gi function | 2 | gastrointestinal disease e . g . active mcLcerative disease uncontrolled nausea vomiting diarrhea | 2 | or small bowel resection a nasogastric tube ng tube is allowed | 1 |
| 17 | 81 | patient with impaired gastrointestinal gi function | 2 | gi disease that may significantly alter the absorption of onc201 uncontrolled nausea vomiting diarrhea | 2 | or small bowel resection that under the judgment of the principal investigator pi may impair absorption of study drugs | 1 |
| 18 | 107 | patients with impaired gastrointestinal gi function | 2 | gi disease that may significantly alter the absorption of oral bgj398 e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 2 | or small bowel resection sufficient to impair absorption of drug | 1 |
| 19 | 2 | patients must be able to take oral medications patients must not have any impairment of gastrointestinal function | 1 | gi disease that may significantly alter the absorption of study drug e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 2 | small bowel resection note gastric bypass is allowed | 1 |
| 20 | 27 | patients may not have any impairment of gastrointestinal function | 1 | gastrointestinal disease that may significantly alter the absorption of blinded drug e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | or small bowel resection are not eligible to participate in this study | 1 |
| 21 | 33 | patients with an impairment of gastrointestinal function | 1 | gastrointestinal disease that may significantly alter the absorption of protocol treatment e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | or any other uncontrolled gastrointestinal condition eg nausea diarrhea or vomiting that might impair the bioavailability of lenvatinib or midazolam . | 1 |
| 22 | 37 | patient has impaired gastrointestinal function | 1 | gastrointestinal disease that may significantly alter the absorption of axitinib e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | clinical signs and symptoms of gastrointestinal obstruction and / or patients who require parenteral hydration and / or nutrition . | 1 |
| 23 | 39 | patient may not have any impairment of gastrointestinal function | 1 | gastrointestinal disease that may significantly alter the absorption of cabozantinib e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | mcLcerative diseases bowel resection with decreased intestinal absorption | 1 |
| 24 | 49 | current impairment of gastrointestinal function | 1 | gastrointestinal disease that may significantly alter the absorption of rad001 i . e . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | or small bowel resection associated with malabsorption . | 1 |
| 25 | 55 | impaired gi function | 1 | gastrointestinal disease that may significantly alter drug absorption e . g . inflammatory bowel disease uncontrolled nausea vomiting diarrhea | 1 | extensive small bowel resection | 1 |
| 26 | 63 | participant has impairment of gastrointestinal gi function | 1 | gastrointestinal disease that may significantly alter the absorption of gdc 0032 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | small bowel resection with decreased intestinal absorption | 1 |
| 27 | 73 | any impairment of gastrointestinal gi function | 1 | gastrointestinal disease that may significantly alter the absorption of azd4547 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | note concomitant therapy with proton pump inhibitors and / or h2 receptor antagonists is permissible | 1 |
| 28 | 86 | ongoing gi adverse events > = grade 2 e . g . nausea vomiting | 1 | gastrointestinal disease that may significantly alter the absorption of everolimus / lapatinib e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | obstruction or stomach and / or small bowel resection | 1 |
| 29 | 91 | patient has impaired gastrointestinal gi function | 1 | gastrointestinal disease that may significantly alter the absorption of abt 888 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | small bowel resection including dependence on a gastrostomy g tube for administration of medications | 1 |
| 30 | 94 | gastrointestinal gi disease | 1 | gastrointestinal disease that may significantly alter the absorption of talazoparib bmn 673 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | or major small bowel resection | 1 |
| 31 | 99 | subject has impairment of gastrointestinal gi function | 1 | gastrointestinal disease e . g . uncontrolled mcLcerative disease uncontrolled nausea vomiting diarrhea chronic | 1 | or inability to swallow up to five ceritinib capsmcLes daily | 1 |
| 32 | 130 | inability to take oral medications e . g . impairment of gastrointestinal gi function | 1 | gastrointestinal disease that may significantly alter the absorption of everolimus e . g . mcLcerative disease uncontrolled nausea vomiting and / or diarrhea | 1 | small bowel resection that requires nutritional support | 1 |
| 33 | 5 | NA | gastrointestinal disease that may significantly alter the absorption of oral medications e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | or small bowel resection patients with unresolved diarrhea will be excluded | 1 | |
| 34 | 6 | NA | gastrointestinal disease e . g . uncontrolled nausea vomiting diarrhea | 1 | small bowel resection within last 1 year or gastric bypass surgery within last 1 year | 1 | |
| 35 | 7 | NA | gastrointestinal disease that may significantly alter the absorption of study medication e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | small bowel resection including dependence on a gastrostomy tube g tube for administration of medications | 1 | |
| 36 | 8 | NA | gastrointestinal disease affecting absorption of buparlisib e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | or gastric or small bowel resection | 1 | |
| 37 | 9 | NA | gastrointestinal disease that comcLd interfere with the absorption of aeb071 or byl719 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | concomitant therapy with antacids and anti emetics is permissible | 1 | |
| 38 | 10 | NA | gastrointestinal disease that may significantly alter the absorption of the drug e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 39 | 11 | NA | gastrointestinal disease that may significantly alter the absorption of pd 0325901 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 40 | 12 | NA | impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the drugs e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea > = common terminology criteria for adverse events ctcae grade 2 | 1 | NA | ||
| 41 | 14 | NA | gastrointestinal disease that may significantly alter the absorption of bibf 1120 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 42 | 15 | NA | gastrointestinal disease that may significantly alter the absorption of sirolimus e . g . active mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 43 | 16 | NA | disease that may significantly alter the absorption of encorafenib or binimetinib e . g . mcLcerative diseases uncontrolled vomiting | 1 | NA | ||
| 44 | 17 | NA | has impairment of gastrointestinal gi function or gi disease that may significantly alter drug absorption e . g . active inflammatory bowel disease uncontrolled nausea vomiting diarrhea or | 1 | NA | ||
| 45 | 18 | NA | gi disease that may significantly alter the absorption of the study drugs e . g . uncontrolled mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 46 | 19 | NA | gi disease that may significantly alter the absorption of dabrafenib and trametinib in the opinion of the treating investigator e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 47 | 20 | NA | gi disease that may significantly alter the absorption of h3b 6545 e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 48 | 21 | NA | gi disease that may significantly alter the absorption of vemurafenib and cobimetinib in the opinion of the treating investigator e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 49 | 23 | NA | gi disease that may significantly alter the absorption of inc280 e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea or | 1 | NA | ||
| 50 | 24 | NA | gi disease that may significantly alter the absorption of oral alpelisib e . g . uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 51 | 25 | NA | gi disease that may significantly alter the absorption of panobinostat or dexamethasone e . g . mcLcerative disease uncontrolled nausea vomiting | 1 | NA | ||
| 52 | 29 | NA | gi disease that may significantly alter the absorption of study medications e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 53 | 30 | NA | gi disease that may significantly alter the absorption of orally administered medication e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea or | 1 | NA | ||
| 54 | 31 | NA | gi disease that may significantly alter the absorption of the study drugs e . g . mcLcerative diseases uncontrolled nausea / vomiting / diarrhea | 1 | NA | ||
| 55 | 32 | NA | gi disease that may significantly alter the absorption of ceritinib e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea or | 1 | NA | ||
| 56 | 34 | NA | gi disease that may significantly alter the absorption of oral drug e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 57 | 35 | NA | gi disease that may significantly alter the absorption of azd1775 e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 58 | 36 | NA | diarrhea at the start of the study patient has impairment of gi function or gi disease that may significantly alter the absorption of ceritinib e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea or | 1 | NA | ||
| 59 | 38 | NA | gi disease that may significantly alter the absorption of oral alpelisib e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 60 | 40 | NA | impairment of gi function e . g . active mcLcerative disease uncontrolled nausea vomiting or diarrhea | 1 | NA | ||
| 61 | 41 | NA | gi disease that may significantly alter the absorption of abemaciclib e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 62 | 42 | NA | gi disease that may significantly alter the absorption of oral mln0128 e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 63 | 43 | NA | gi disease that may significantly alter the absorption of mocetinostat e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 64 | 44 | NA | gi disease that may significantly alter absorption of oral capecitabine e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 65 | 45 | NA | gi disease that may significantly alter the absorption of bkm120 or byl719 e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 66 | 46 | NA | gi disease that may significantly alter the absorption of buparlisib eg mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 67 | 47 | NA | gi disease that may significantly alter the absorption of drug e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 68 | 48 | NA | active gi disease that may significantly alter the absorption of study drug in the opinion of the treating physician e . g . active mcLcerative diseases uncontrolled nausea uncontrolled vomiting uncontrolled diarrhea active | 1 | NA | ||
| 69 | 50 | NA | gi disease that may significantly alter the absorption of mek162 e . g . mcLcerative disease uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 70 | 51 | NA | gi disease that may significantly alter the absorption of wnt974 e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 71 | 52 | NA | gi disease that may significantly alter the absorption of dovitinib e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 72 | 53 | NA | gi disease that may significantly alter the absorption of oral medications e . g . mcLcerative diseases uncontrolled nausea vomiting diarrhea | 1 | NA | ||
| 73 | 61 | NA | has impairment of gastrointestinal gi function or gi disease that may significantly alter drug absorption including but not limited to active inflammatory bowel disease | 1 | NA |